Search

Author/Creator Stelitano, C.

1. ANAPLASTIC LARGE CELL LYMPHOMA, ALK‐NEGATIVE: ANALYSIS OF 235 CASES COLLECTED BY THE T‐CELL PROJECT. (12th June 2019)

Authors:
Shustov, A.; Cabrera, M.; Bellei, M.; Civallero, M.; Ko, Y.H.; Manni, M.; Horwitz, S.M.; Antonio De Souza, C.; Radford, J.; Varela, S.B.; Prates, M.V.; Ferreri, A.; Chiattone, C.; Spina, M.; Vose, J.M.; Chiappella, A.; Laszlo, D.; Marino, D.; Stelitano, C.; Skrypets, T.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
283
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. CLINICAL CHARACTERISTICS OF PATIENTS WITH NEGATIVE INTERIM‐PET AND POSITIVE FINAL PET: DATA FROM THE PROSPECTIVE PET‐ORIENTED HD0801 STUDY BY FONDAZIONE ITALIANA LINFOMI (FIL). (June 2017)

Authors:
Rigacci, L.; Puccini, B.; Zinzani, P.; Kovalchuk, S.; Broccoli, A.; Evangelista, A.; Gioia, D.; Mannelli, L.; Castagnoli, A.; Santoro, A.; Bonfichi, M.; Rossi, G.; Anastasia, A.; Zaja, F.; Vitolo, U.; Pavone, V.; Pulsoni, A.; Gaidano, G.; Stelitano, C.; Salvi, F.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
38
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY. (12th June 2019)

Authors:
Ferrero, S.; Ladetto, M.; Beldjord, K.; Drandi, D.; Stelitano, C.; Bernard, S.; Castagnari, B.; Bouabdallah, K.; Cesaretti, M.; Alvarez, I.; Gressin, R.; Ponzoni, M.; Tripodo, C.; Traverse‐Glehen, A.; Baseggio, L.; Liberati, A.; Merli, M.; Tessoulin, B.; Patti, C.; Cabras, M.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
224
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. LONG TERM RESULTS OF THE FOLL05 RANDOMIZED STUDY COMPARING R‐CVP WITH R‐CHOP AND R‐FM AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. A FIL STUDY. (June 2017)

Authors:
Luminari, S.; Tarantino, V.; Anastasia, A.; Boccomini, C.; Chiarenza, A.; Rigacci, L.; Angelucci, E.; Ferrari, A.; Pulsoni, A.; Rattotti, S.; Angrilli, F.; Gaidano, G.; Stelitano, C.; Bertoldero, G.; Cascavilla, N.; Salvi, F.; Ferreri, A.J.; Vallisa, D.; Balzarotti, M.; Cox, M.C.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
34
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. LONG‐TERM EFFICACY AND SAFETY OF LENALIDOMIDE MAINTENANCE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT ELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION (ASCT). (12th June 2019)

Authors:
Ferreri, A.J.; Sassone, M.C.; Angelillo, P.; Zaja, F.; Re, A.; Spina, M.; Di Rocco, A.; Fabbri, A.; Stelitano, C.; Frezzato, M.; Rusconi, C.; Zambello, R.; Arcari, A.; Bertoldero, G.; De Lorenzo, D.; Volpetti, S.; Calimeri, T.; Perrone, S.; Cecchetti, C.; Ciceri, F.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
256
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. OC-0502 Role of consolidation RT to bulky lesions of advanced Hodgkin lymphoma: results of FIL HD0801 trial. (April 2019)

Authors:
Ricardi, U.; Levis, M.; Evangelista, A.; Gioia, D.M.; Rigacci, L.; Botto, B.; Simontacchi, G.; Franzone, P.; Rossi, G.; Buglione, M.; Pavone, V.; Bonfichi, M.; Rusconi, C.; Freilone, R.; Pulsoni, A.; De Sanctis, V.; Gaidano, G.; Stelitano, C.; Tani, M.; Castagnoli, A.
Journal:
Radiotherapy and oncology
Issue:
Volume 133(2019)Supplement 1
Page Start:
S258
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. P1144: RADIOIMMUNOTHERAPY (RIT) VERSUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ASCT) IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA: A FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III TRIAL. (23rd June 2022)

Authors:
Ladetto, M.; Tavarozzi, R.; Evangelista, A.; Zanni, M.; Tucci, A.; Anastasia, A.; Botto, B.; Boccomini, C.; Bolis, S.; Volpetti, S.; Zilioli, V. R.; Puccini, B.; Arcari, A.; Pavone, V.; Gaidano, G.; Corradini, P.; Tani, M.; Ferrero, S.; Cavallo, F.; Milone, G.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1032
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. POD24 AND CR30 ARE PROMISING SURROGATE ENDPOINTS FOR ASSESSING THE OUTCOME OF PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA ENROLLED IN THE FOLL05 TRIAL BY FIL. (June 2017)

Authors:
Luminari, S.; Marcheselli, L.; Manni, M.; Anastasia, A.; Vitolo, U.; Chiarenza, A.; Rigacci, L.; Angelucci, E.; Fama, A.; Pulsoni, A.; Rattotti, S.; Angrilli, F.; Gaidano, G.; Stelitano, C.; Bertoldero, G.; Cascavilla, N.; Salvi, F.; Ferreri, A.J.; Tarantino, V.; Bellei, M.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
228
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. S221: BORTEZOMIB TO R-DHAP COMPARED TO R-DHAP IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ELIGIBLE TO STEM CELL TRANPLANTATION: FINAL RESULTS OF PHASE II RANDOMIZED FIL-VERAL12. (23rd June 2022)

Authors:
Chiappella, A.; Balzarotti, M.; Botto, B; Castiglione, A.; Cavallo, F.; Usai, S. V.; Zanni, M.; Califano, C.; Re, F.; Ghiggi, C.; Olivieri, A.; Corradini, P.; Liberati, A. M.; Volpetti, S.; Michieli, M. G.; Tucci, A; Gaidano, G.; Tani, M.; Ciambelli, F.; Musuraca, G.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
122
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗